What is BioCryst Pharmaceuticals Inc's earnings per share (EPS)?

BioCryst Pharmaceuticals Inc (BCRX) reported diluted earnings per share of $1.21 for fiscal year 2025. This represents a 381.4% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

BioCryst Pharmaceuticals Inc (BCRX) Financials

BCRX

Trailing 12 months to June 30, 2026

Revenue $940.6M +68.7% YoY

Net Income -$384.7M -977.2% YoY

EPS (Diluted) -$1.49 -727.8% YoY

Free Cash Flow $373.4M +2269.0% YoY

Market Cap $2.2B as of Oct 10, 2026

Price / Sales 2.3x on $940.6M revenue, trailing 12 months to June 30, 2026

Price / Earnings n/m net loss, so no earnings multiple, trailing 12 months to June 30, 2026

Price / Book n/m negative shareholder equity, so no book multiple, Q2 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 10, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q2 FY2026, ended Jun 30, 2026 Reported Aug 5, 2026 Currency USD FYE December

Newest figures come from the 10-Q for Q2 FY2026, filed Aug 5, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the BCRX SEC filings page.

BioCryst Pharmaceuticals Inc (BCRX) reported $940.6M in revenue over the twelve months to Jun 30, 2026, up 68.7% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI BCRX FY2025 2026-10-03

A 2025 scale inflection converted years of cash-consuming development into operating cash, but liabilities still exceed assets.

The 2025 shift is unusually cash-backed: operating cash flow of $347M nearly matched free cash flow of $345M, so reported earnings translated into cash rather than being absorbed by reinvestment. Unlike FY2024, when operating cash flow and free cash flow were outflows of $52M and $53M, respectively, this marks a change in earnings quality, not just profitability.

Revenue nearly doubled into FY2025 while operating margin reached 39.0% from near break-even in FY2024; the scale effect suggests fixed-cost absorption or a material mix shift, not merely lower spending.

Long-term debt fell to $0 in FY2025 alongside a financing cash outflow of $350M, indicating that operating cash was largely offset by financing uses. Yet liabilities of $633M still exceeded assets of $514M, so profitability improved before the balance sheet fully normalized.

Financial Health Signals

Financial Health Score 74/100

Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →

Health score ≠ stock price. This rates the quality of BioCryst Pharmaceuticals Inc's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Profitability

BioCryst Pharmaceuticals Inc has an operating margin of 39.0%, meaning the company retains $39 of operating profit per $100 of revenue. This results in a moderate score of 59/100, indicating healthy but not exceptional operating efficiency. This is up from -0.6% the prior year.

Growth

BioCryst Pharmaceuticals Inc's revenue surged 94.1% year-over-year to $874.8M, reflecting rapid business expansion. This strong growth earns a score of 96/100.

Leverage

Liquidity

BioCryst Pharmaceuticals Inc's current ratio of 2.06 indicates adequate short-term liquidity, earning a score of 60/100. The company can meet its near-term obligations, though with limited headroom.

Cash Flow

BioCryst Pharmaceuticals Inc converts 39.4% of revenue into free cash flow ($344.9M). This strong cash generation earns a score of 66/100.

Returns

Altman Z-Score Grey Zone

2.34

BioCryst Pharmaceuticals Inc scores 2.34, placing it in the grey zone between 1.81 and 2.99. The score is driven primarily by a large market capitalization ($2.2B) relative to total liabilities ($633.3M). This signals moderate financial risk that warrants monitoring.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Strong

7/9

BioCryst Pharmaceuticals Inc passes 7 of 9 financial strength tests. All 4 profitability signals pass (positive income, cash flow, and earnings quality), 1 of 3 leverage/liquidity signals pass, both operating efficiency signals pass.

Earnings Quality Cash-Backed

1.32x

For every $1 of reported earnings, BioCryst Pharmaceuticals Inc generates $1.32 in operating cash flow ($347.4M OCF vs $263.9M net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.

Interest Coverage Adequate

4.32x

BioCryst Pharmaceuticals Inc earns $4.32 in operating income for every $1 of interest expense ($341.0M vs $78.9M). This adequate coverage means the company can meet its interest obligations, but has limited cushion if earnings fall.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$218.3M

YoY+33.6%

QoQ+39.5%

5Y CAGR+34.3%

10Y CAGR+46.5%

BioCryst Pharmaceuticals Inc generated $218.3M in revenue in Q2 2026. This represents an increase of 33.6% from the same quarter a year earlier. Against the prior quarter it is up 39.5%.

EBITDA

$99.3M

QoQ+114.2%

BioCryst Pharmaceuticals Inc's EBITDA was $99.3M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. Against the prior quarter it is up 114.2%.

Net Income

$78.4M

YoY+1441.7%

QoQ+110.9%

BioCryst Pharmaceuticals Inc reported $78.4M in net income in Q2 2026. This represents an increase of 1441.7% from the same quarter a year earlier. Against the prior quarter it is up 110.9%.

EPS (Diluted)

$0.30

YoY+1400.0%

QoQ+110.1%

BioCryst Pharmaceuticals Inc earned $0.30 per diluted share (EPS) in Q2 2026. This represents an increase of 1400.0% from the same quarter a year earlier. Against the prior quarter it is up 110.1%.

Cash & Balance Sheet

Free Cash Flow

$104.1M

YoY+153.2%

QoQ+267.4%

BioCryst Pharmaceuticals Inc generated $104.1M in free cash flow in Q2 2026, representing cash available after capex. This represents an increase of 153.2% from the same quarter a year earlier. Against the prior quarter it is up 267.4%.

Cash & Debt

$155.0M

YoY+76.0%

QoQ-9.7%

5Y CAGR-5.9%

10Y CAGR+33.4%

BioCryst Pharmaceuticals Inc held $155.0M in cash against $395.4M in long-term debt as of Q2 2026.

Shares Outstanding

256M

YoY+21.7%

QoQ+0.5%

5Y CAGR+7.4%

10Y CAGR+13.2%

BioCryst Pharmaceuticals Inc had 256M shares outstanding in Q2 2026. This represents an increase of 21.7% from the same quarter a year earlier. Against the prior quarter it is up 0.5%.

Dividends Per Share

Not reported for Q2 2026.

Margins & Returns

Gross Margin

98.2%

YoY0.0pp

QoQ+1.7pp

5Y change-1.2pp

BioCryst Pharmaceuticals Inc's gross margin was 98.2% in Q2 2026, indicating the percentage of revenue retained after direct costs. That is unchanged from the same quarter a year earlier. Against the prior quarter it is up 1.7 percentage points.

Operating Margin

45.1%

YoY+26.9pp

5Y change+104.3pp

BioCryst Pharmaceuticals Inc's operating margin was 45.1% in Q2 2026, reflecting core business profitability. This is up 26.9 percentage points from the same quarter a year earlier.

Net Margin

35.9%

YoY+32.8pp

5Y change+122.4pp

BioCryst Pharmaceuticals Inc's net profit margin was 35.9% in Q2 2026, showing the share of revenue converted to profit. This is up 32.8 percentage points from the same quarter a year earlier.

Return on Equity

Not reported for Q2 2026.

Capital Allocation

R&D Spending

$52.0M

YoY+19.8%

QoQ-13.8%

5Y CAGR-0.3%

BioCryst Pharmaceuticals Inc invested $52.0M in research and development in Q2 2026. This represents an increase of 19.8% from the same quarter a year earlier. Against the prior quarter it is down 13.8%.

Capital Expenditures

$209K

YoY+16.8%

QoQ-48.1%

5Y CAGR-23.8%

10Y CAGR-19.5%

BioCryst Pharmaceuticals Inc invested $209K in capex in Q2 2026, funding long-term assets and infrastructure. This represents an increase of 16.8% from the same quarter a year earlier. Against the prior quarter it is down 48.1%.

Share Buybacks

Not reported for Q2 2026.

BCRX Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

BCRX quarterly income statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Revenue	$940.6M	$874.8M+94.1%	$450.7M+36.0%	$331.4M+22.4%	$270.8M+72.3%	$157.2M+782.4%	$17.8M-63.5%	$48.8M+136.5%	$20.7M-18.0%	$25.2M-4.4%	$26.4M-45.4%	$48.3M+254.6%	$13.6M-21.5%	$17.3M-34.1%	$26.3M+33.9%	$19.6M
Cost of Revenue	$20.9M	$19.1M+55.5%	$12.3M+173.8%	$4.5M-30.1%	$6.4M-11.4%	$7.2M+366.4%	$1.6M-58.4%	$3.7M	N/A	$1.1M-50.3%	$2.3M+67.9%	$1.4M+136700.0%	$1K	N/A	N/A	N/A
Gross Profit	$919.7M	$855.8M+95.2%	$438.4M+34.1%	$326.9M+23.6%	$264.4M+76.3%	$149.9M+822.0%	$16.3M-63.9%	$45.1M	N/A	$24.0M0.0%	$24.1M-48.7%	$46.9M+244.6%	$13.6M	N/A	N/A	N/A
R&D Expenses	$197.8M	$166.1M-4.9%	$174.6M-19.4%	$216.6M-14.5%	$253.3M+21.3%	$208.8M+69.8%	$123.0M+14.8%	$107.1M+26.1%	$84.9M+26.8%	$67.0M+9.8%	$61.0M-16.1%	$72.8M+40.5%	$51.8M+23.5%	$41.9M-14.7%	$49.2M-14.1%	$57.2M
SG&A Expenses	$337.3M	$348.6M+30.9%	$266.3M+24.4%	$214.1M+34.3%	$159.4M+34.1%	$118.8M+74.9%	$67.9M+83.0%	$37.1M+25.8%	$29.5M+111.8%	$13.9M+23.8%	$11.3M-13.8%	$13.0M+74.9%	$7.5M+24.2%	$6.0M-34.2%	$9.1M-23.8%	$12.0M
Operating Income	-$313.2M	$341.0M+13508.9%	-$2.5M+97.5%	-$103.7M+30.1%	-$148.4M+16.5%	-$177.7M-1.7%	-$174.8M-75.7%	-$99.5M-5.6%	-$94.2M-64.1%	-$57.4M-18.1%	-$48.6M-23.2%	-$39.4M+13.8%	-$45.8M-49.0%	-$30.7M+9.4%	-$33.9M+31.7%	-$49.6M
EBITDA	N/A	$342.4M+26497.7%	-$1.3M+98.7%	-$102.1M+30.6%	-$147.0M+16.9%	-$176.9M-1.7%	-$174.0M-76.2%	-$98.7M-5.7%	-$93.5M-64.8%	-$56.7M-17.8%	-$48.1M-22.6%	-$39.3M+13.9%	-$45.6M-49.9%	-$30.4M+8.6%	-$33.3M+31.7%	-$48.7M
Interest Expense	$75.3M	$78.9M-19.9%	$98.5M-9.0%	$108.2M+9.2%	$99.1M+67.1%	$59.3M+308.9%	$14.5M+21.9%	$11.9M+29.6%	$9.2M+7.1%	$8.6M+32.0%	$6.5M+24.8%	$5.2M+4.0%	$5.0M+4.6%	$4.8M+2.4%	$4.7M+23.6%	$3.8M
Income Tax	$3.5M	$3.5M+83.2%	$1.9M+521.6%	$310K-88.7%	$2.7M+21.3%	$2.3M	$0	$0	$0	$0	$0	$0-100.0%	$17.3M+102.1%	$8.6M+22.4%	$7.0M	N/A
Net Income	-$384.7M	$263.9M+396.9%	-$88.9M+60.8%	-$226.5M+8.3%	-$247.1M-34.3%	-$184.1M-0.7%	-$182.8M-67.9%	-$108.9M-7.6%	-$101.3M-53.9%	-$65.8M-19.3%	-$55.1M-28.2%	-$43.0M+4.8%	-$45.2M-50.1%	-$30.1M+23.0%	-$39.1M+31.4%	-$56.9M
EPS (Basic)	N/A	$1.26+393.0%	-$0.43+63.6%	-$1.18+11.3%	-$1.33-29.1%	-$1.03+5.5%	-$1.09	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
EPS (Diluted)	-$1.49	$1.21+381.4%	-$0.43+63.6%	-$1.18+11.3%	-$1.33-29.1%	-$1.03+5.5%	-$1.09	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Diluted Shares (Avg)	N/A	219M+5.7%	207M+7.5%	192M+3.4%	186M+3.8%	179M+7.1%	167M+44.7%	116M+12.0%	103M+22.2%	84M+14.6%	74M+1.1%	73M+9.2%	67M+20.9%	55M	N/A	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Revenue	$218.3M+33.6%	$156.4M+7.5%	$406.6M+209.1%	$159.4M+36.1%	$163.4M+49.4%	$145.5M+56.9%	$131.5M+40.8%	$117.1M+35.0%
Cost of Revenue	$3.8M+37.2%	$5.4M+17.7%	$9.5M+56.3%	$2.2M-31.9%	$2.8M+64.7%	$4.6M+261.1%	$6.1M+291.4%	$3.2M+192.2%
Gross Profit	$214.4M+33.5%	$151.0M+7.1%	$397.0M+216.5%	$157.2M+38.1%	$160.6M+49.2%	$141.0M+54.1%	$125.4M+36.6%	$113.9M+33.0%
R&D Expenses	$52.0M+19.8%	$60.3M+61.8%	$40.9M-17.3%	$44.6M+8.6%	$43.4M+15.3%	$37.3M-19.8%	$49.4M-29.4%	$41.1M-12.4%
SG&A Expenses	$64.0M-26.8%	$94.6M+14.7%	$95.8M+19.0%	$83.0M+27.5%	$87.4M+42.7%	$82.5M+38.6%	$80.5M+24.7%	$65.1M+28.5%
Operating Income	$98.5M+230.6%	-$701.6M-3405.2%	$260.4M+5876.1%	$29.6M+284.7%	$29.8M+240.0%	$21.2M+246.5%	-$4.5M+89.4%	$7.7M+164.5%
EBITDA	$99.3M	-$700.2M-3347.8%	N/A	N/A	N/A	$21.6M+252.0%	-$4.2M+90.1%	$8.0M+169.6%
Interest Expense	$21.7M+0.6%	$19.8M-15.8%	$14.1M-42.2%	$19.7M-20.8%	$21.6M-12.7%	$23.5M-4.1%	$24.4M-0.5%	$24.8M-9.2%
Income Tax	$1.1M-23.0%	$1.0M+38.3%	$2.2M+170.1%	-$769K-231.2%	$1.4M+714.5%	$726K+98.9%	$804K+156.2%	$586K+77.6%
Net Income	$78.4M+1441.7%	-$721.8M-2255762.5%	$245.8M+1017.5%	$12.9M+191.9%	$5.1M+140.1%	$32K+100.1%	-$26.8M+56.6%	-$14.0M+61.2%
EPS (Basic)	$0.31+1450.0%	-$2.98	$1.17+1000.0%	$0.06+185.7%	$0.02+133.3%	$0.00+100.0%	-$0.13+58.1%	-$0.07+63.2%
EPS (Diluted)	$0.30+1400.0%	-$2.98	$1.13+969.2%	$0.06+185.7%	$0.02+133.3%	$0.00+100.0%	-$0.13+58.1%	-$0.07+63.2%
Diluted Shares (Avg)	265M+20.6%	242M+12.5%	N/A	220M+6.3%	220M+6.5%	215M+4.5%	N/A	207M+9.1%

BCRX Balance Sheet

BCRX quarterly balance sheet

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Total Assets	$514.2M+4.8%	$490.4M-5.1%	$517.0M-6.0%	$550.0M-6.5%	$588.2M+75.7%	$334.7M+91.0%	$175.3M+19.4%	$146.8M-17.6%	$178.3M+98.4%	$89.8M-26.6%	$122.4M-10.6%	$136.9M+180.1%	$48.9M-14.9%	$57.4M-30.1%	$82.2M
Current Assets	$404.3M-4.2%	$422.0M-14.9%	$496.0M-4.0%	$516.5M-8.8%	$566.1M+74.8%	$323.8M+97.0%	$164.3M+43.7%	$114.4M-8.8%	$125.4M+87.2%	$67.0M+5.0%	$63.8M-28.6%	$89.3M+112.1%	$42.1M+0.3%	$42.0M-20.6%	$52.9M
Cash & Equivalents	$89.7M-14.3%	$104.7M-5.4%	$110.6M-63.7%	$304.8M-39.6%	$504.4M+85.4%	$272.1M+138.3%	$114.2M+327.1%	$26.7M-46.8%	$50.3M+127.5%	$22.1M-23.5%	$28.9M-47.0%	$54.5M+157.7%	$21.2M+1.3%	$20.9M+27.0%	$16.4M
Short-Term Investments	$185.0M-14.4%	$216.1M-22.3%	$278.3M+132.8%	$119.5M+3621.8%	$3.2M-88.6%	$28.2M+28.0%	$22.1M-71.6%	$77.7M+21.2%	$64.1M+97.0%	$32.5M+43.6%	$22.7M+24.3%	$18.2M+7.9%	$16.9M+14.8%	$14.7M-41.8%	$25.3M
Inventory	$5.4M-33.3%	$8.1M-71.8%	$28.7M+4.2%	$27.5M+74.4%	$15.8M+124.3%	$7.0M	$0-100.0%	$1.6M	N/A	$500K-69.0%	$1.6M+136.0%	$683K-82.8%	$4.0M0.0%	$4.0M+1413.3%	$263K
Accounts Receivable	$106.8M+35.1%	$79.1M+38.8%	$57.0M+12.6%	$50.6M+72.0%	$29.4M+240.2%	$8.6M-61.0%	$22.1M+415.9%	$4.3M-29.8%	$6.1M-30.2%	$8.8M+40.4%	$6.2M	N/A	N/A	N/A	N/A
Long-Term Investments	$61.2M+201.0%	$20.3M	$0-100.0%	$18.1M+164.7%	$6.8M	$0	$0-100.0%	$22.4M-45.8%	$41.3M+362.6%	$8.9M-81.3%	$47.7M+16.0%	$41.1M+1492.4%	$2.6M+124.3%	$1.2M-92.5%	$15.4M
Total Liabilities	$633.3M-34.5%	$966.4M-0.6%	$972.5M+15.1%	$844.6M+21.5%	$695.1M+96.4%	$354.0M+158.3%	$137.0M+40.4%	$97.6M+3.3%	$94.5M+7.1%	$88.3M+18.3%	$74.6M+21.9%	$61.2M+22.5%	$50.0M-13.6%	$57.9M-14.1%	$67.4M
Current Liabilities	$196.1M+22.2%	$160.4M+6.9%	$150.0M+42.1%	$105.5M+1.7%	$103.7M-1.8%	$105.7M+14.4%	$92.3M+32.9%	$69.5M-7.2%	$74.8M+37.7%	$54.4M-12.7%	$62.3M+8.7%	$57.3M+275.5%	$15.3M-11.4%	$17.2M-34.5%	$26.3M
Non-Current Liabilities	$437.2M-45.7%	$806.0M-2.0%	$822.5M+11.3%	$739.1M+25.0%	$591.4M+138.2%	$248.3M+455.6%	$44.7M+58.9%	$28.1M+43.1%	$19.7M-42.0%	$33.9M+173.9%	$12.4M+213.7%	$3.9M-88.6%	$34.7M-14.6%	$40.7M-1.1%	$41.1M
Long-Term Debt	$0-100.0%	$314.9M+3.8%	$303.2M+30.9%	$231.6M+70.2%	$136.1M+13.7%	$119.7M	N/A	$30.0M+30.4%	$23.0M0.0%	$23.0M	N/A	N/A	N/A	N/A	N/A
Total Equity	-$119.2M+75.0%	-$475.9M-4.5%	-$455.5M-54.6%	-$294.6M-175.4%	-$107.0M-455.4%	-$19.3M-150.4%	$38.3M-22.3%	$49.2M-41.2%	$83.8M+5208.4%	$1.6M-96.7%	$47.7M-36.9%	$75.6M+6817.1%	-$1.1M-148.0%	-$454K-103.1%	$14.8M
Retained Earnings	-$1.5B+14.9%	-$1.8B-5.3%	-$1.7B-15.6%	-$1.5B-20.5%	-$1.2B-18.0%	-$1.0B-21.7%	-$840.6M-14.8%	-$732.0M-15.8%	-$631.8M-11.6%	-$566.1M-10.8%	-$510.9M-9.2%	-$467.9M-10.7%	-$422.7M-7.7%	-$392.6M-11.1%	-$353.5M

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Total Assets	$557.9M+22.0%	$465.1M-3.1%	$514.2M+4.8%	$446.4M-9.1%	$457.2M-3.2%	$480.0M+2.6%	$490.4M-5.1%	$491.3M-6.1%
Current Assets	$484.7M+21.6%	$373.6M-8.9%	$404.3M-4.2%	$355.7M-16.7%	$398.5M+9.6%	$410.0M-8.3%	$422.0M-14.9%	$427.1M-15.0%
Cash & Equivalents	$155.0M+76.0%	$171.6M+63.1%	$89.7M-14.3%	$84.1M-13.2%	$88.0M+12.3%	$105.2M+24.7%	$104.7M-5.4%	$96.8M-35.8%
Short-Term Investments	$197.6M+14.9%	$66.8M-64.8%	$185.0M-14.4%	$128.8M-44.8%	$172.0M-11.2%	$189.9M-24.7%	$216.1M-22.3%	$233.2M-5.5%
Inventory	$6.1M+20.1%	$6.0M-12.9%	$5.4M-33.3%	$5.2M-30.8%	$5.0M+13.3%	$6.9M-76.9%	$8.1M-71.8%	$7.6M-74.5%
Accounts Receivable	$110.8M+21.5%	$109.3M+17.0%	$106.8M+35.1%	$91.3M+26.0%	$91.2M+32.6%	$93.4M+54.2%	$79.1M+38.8%	$72.5M+35.1%
Long-Term Investments	$0-100.0%	$20.6M+0.1%	$61.2M+201.0%	$39.7M+104.2%	$10.1M-84.3%	$20.5M	$20.3M	$19.4M
Total Liabilities	$1.0B+15.2%	$1.0B+9.3%	$633.3M-34.5%	$834.3M-13.1%	$878.8M-7.3%	$932.0M-1.3%	$966.4M-0.6%	$959.8M+2.8%
Current Liabilities	$208.8M+17.9%	$195.4M+39.7%	$196.1M+22.2%	$190.2M+23.9%	$177.2M+37.3%	$139.9M+16.6%	$160.4M+6.9%	$153.6M+69.2%
Non-Current Liabilities	$803.3M+14.5%	$823.5M+4.0%	$437.2M-45.7%	$644.1M-20.1%	$701.6M-14.3%	$792.1M-3.9%	$806.0M-2.0%	$806.3M-4.4%
Long-Term Debt	$395.4M+62.9%	$395.2M+25.3%	N/A	$194.4M-38.2%	$242.8M-22.6%	$315.4M+2.2%	$314.9M+3.8%	$314.3M+5.5%
Total Equity	-$454.3M-7.8%	-$553.8M-22.6%	-$119.2M+75.0%	-$387.9M+17.2%	-$421.6M+11.4%	-$451.9M+5.1%	-$475.9M-4.5%	-$468.6M-14.0%
Retained Earnings	-$2.1B-21.8%	-$2.2B-25.9%	-$1.5B+14.9%	-$1.8B-0.5%	-$1.8B-2.1%	-$1.8B-3.1%	-$1.8B-5.3%	-$1.7B-7.6%

Not reported in any period shown, so not listed: Goodwill.

BCRX Cash Flow Statement

BCRX quarterly cash flow statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Operating Cash Flow	$376.1M	$347.4M+767.8%	-$52.0M+45.3%	-$95.1M+41.2%	-$161.8M-13.9%	-$142.2M-5.2%	-$135.1M-50.8%	-$89.6M+3.2%	-$92.6M-125.0%	-$41.1M+23.0%	-$53.4M-307.4%	-$13.1M+66.0%	-$38.6M-45.3%	-$26.5M+29.1%	-$37.4M-16.0%	-$32.3M
Depreciation & Amortization	N/A	$1.4M+11.5%	$1.2M-24.7%	$1.7M+15.2%	$1.4M+84.9%	$777K+3.9%	$748K+3.3%	$724K-6.0%	$770K+9.4%	$704K+45.8%	$483K+168.3%	$180K+1.7%	$177K-41.8%	$304K-51.6%	$628K-29.1%	$886K
Stock-Based Compensation	N/A	$85.1M+30.0%	$65.4M+17.6%	$55.6M+24.4%	$44.7M+29.0%	$34.6M+134.1%	$14.8M-16.5%	$17.7M+88.6%	$9.4M-25.6%	$12.6M+48.7%	$8.5M-12.6%	$9.7M-4.6%	$10.2M+133.0%	$4.4M+4.8%	$4.2M-12.7%	$4.8M
Capital Expenditures	$2.8M	$2.5M+119.6%	$1.1M-48.2%	$2.2M+60.5%	$1.4M-43.4%	$2.4M+364.0%	$514K+49.9%	$343K-6.3%	$366K+11.6%	$328K-93.8%	$5.3M+3.0%	$5.1M+4732.1%	$106K+253.3%	$30K-73.5%	$113K+105.5%	$55K
Free Cash Flow	$373.4M	$344.9M+749.0%	-$53.1M+45.4%	-$97.3M+40.4%	-$163.2M-12.9%	-$144.5M-6.6%	-$135.6M-50.8%	-$89.9M+3.2%	-$92.9M-124.1%	-$41.5M+29.4%	-$58.7M-221.9%	-$18.2M+52.8%	-$38.7M-45.5%	-$26.6M+29.2%	-$37.5M-16.1%	-$32.3M
Investing Cash Flow	-$448.7M	-$13.7M-126.0%	$52.6M+140.0%	-$131.5M-2.5%	-$128.2M-911.4%	$15.8M+330.5%	-$6.9M-108.8%	$77.9M+1534.5%	$4.8M+107.4%	-$64.6M-377.8%	$23.3M+229.3%	-$18.0M	N/A	-$3.5M-113.9%	$24.9M+119.9%	$11.3M
Financing Cash Flow	$124.6M	-$349.9M-5974.1%	-$5.8M-117.7%	$32.5M-63.1%	$88.0M-75.5%	$359.7M+19.7%	$300.6M+203.3%	$99.1M+58.5%	$62.5M-53.9%	$135.7M+482.3%	$23.3M+325.3%	$5.5M	N/A	$30.3M+78.5%	$17.0M-28.6%	$23.8M
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$61K

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Operating Cash Flow	$104.3M+152.6%	-$61.8M-124.6%	$292.0M+5700.6%	$41.6M+404.8%	$41.3M+3119.2%	-$27.5M+48.7%	-$5.2M+41.5%	$8.2M+141.4%
Depreciation & Amortization	$879K	$1.4M+334.4%	$394K+27.5%	N/A	N/A	$331K+8.2%	$309K-27.0%	$311K-26.0%
Stock-Based Compensation	$14.7M-31.0%	$16.0M-25.0%	N/A	$18.6M+7.8%	$21.3M+61.7%	$21.4M+56.5%	N/A	$17.2M+40.5%
Capital Expenditures	$209K+16.8%	$403K+181.8%	$802K+18.8%	$1.3M+2178.0%	$179K+15.5%	$143K-39.1%	$675K+21.8%	$59K-94.0%
Free Cash Flow	$104.1M+153.2%	-$62.2M-124.9%	$291.2M+5044.9%	$40.3M+392.1%	$41.1M+2800.1%	-$27.7M+48.7%	-$5.9M+37.8%	$8.2M+139.2%
Investing Cash Flow	-$110.1M-478.2%	-$268.6M-1091.5%	-$83.5M-569.1%	$13.6M+59.9%	$29.1M+1289.3%	$27.1M-5.8%	$17.8M+162.5%	$8.5M-63.3%
Financing Cash Flow	-$11.2M+84.9%	$412.6M+77887.1%	-$218.0M-5320.5%	-$58.8M-4716.5%	-$73.7M-3648.0%	$529K+150.5%	-$4.0M-26.7%	$1.3M+4.0%

Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.

BCRX Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

BCRX quarterly financial ratios

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Gross Margin	97.8%+0.5pp	97.3%-1.4pp	98.7%+1.0pp	97.6%+2.2pp	95.4%+4.1pp	91.3%-1.1pp	92.4%	N/A	95.5%+4.2pp	91.3%-5.9pp	97.2%-2.8pp	100.0%	N/A	N/A	N/A
Operating Margin	39.0%+39.5pp	-0.6%+30.7pp	-31.3%+23.5pp	-54.8%	-113.1%	-981.1%	-203.7%	-456.2%	-228.0%	-184.4%	-81.7%	-336.4%	-177.2%	-128.9%	-252.4%
Net Margin	30.2%+49.9pp	-19.7%+48.6pp	-68.4%+22.9pp	-91.2%	-117.1%	-1026.4%	-223.0%	-490.3%	-261.2%	-209.2%	-89.1%	-332.1%	-173.7%	-148.6%	-289.9%
Return on Equity	N/A	N/A	N/A	N/A	N/A	N/A	-284.7%-79.0pp	-205.7%-127.1pp	-78.5%+3416.0pp	-3494.6%-3404.4pp	-90.1%-30.4pp	-59.8%	N/A	N/A	-384.6%
Return on Assets	51.3%+69.4pp	-18.1%+25.7pp	-43.8%+1.1pp	-44.9%-13.6pp	-31.3%+23.3pp	-54.6%+7.5pp	-62.1%+6.8pp	-69.0%-32.0pp	-36.9%+24.5pp	-61.4%-26.2pp	-35.2%-2.1pp	-33.0%+28.6pp	-61.6%+6.4pp	-68.0%+1.2pp	-69.3%
Current Ratio	2.06-0.6x	2.63-0.7x	3.31-1.6x	4.90-0.6x	5.46+2.4x	3.06+1.3x	1.78+0.1x	1.650.0x	1.68+0.4x	1.23+0.2x	1.02-0.5x	1.56-1.2x	2.76+0.3x	2.44+0.4x	2.01
Debt-to-Equity	N/A	N/A	N/A	N/A	N/A	N/A	3.58+3.0x	0.61+0.3x	0.27-14.3x	14.58+13.0x	1.56+0.8x	0.81	N/A	N/A	4.55
Asset Turnover	1.70+0.8x	0.92+0.3x	0.64+0.1x	0.49+0.2x	0.27+0.2x	0.05-0.2x	0.28+0.1x	0.140.0x	0.14-0.2x	0.29-0.1x	0.39+0.3x	0.10-0.3x	0.35-0.1x	0.46+0.2x	0.24
FCF Margin	39.4%+51.2pp	-11.8%+17.6pp	-29.4%+30.9pp	-60.3%+31.7pp	-92.0%	-761.4%	-184.1%	-450.0%	-164.7%	-222.8%	-37.8%	-284.1%	-153.3%	-142.7%	-164.5%

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Gross Margin	98.2%0.0pp	96.6%-0.3pp	97.7%+2.3pp	98.6%+1.4pp	98.3%-0.2pp	96.9%-1.8pp	95.4%-3.0pp	97.3%-1.5pp
Operating Margin	45.1%+26.9pp	-448.6%	64.0%+67.5pp	18.6%+12.0pp	18.2%+10.2pp	14.6%+30.2pp	-3.4%+42.3pp	6.6%+20.3pp
Net Margin	35.9%+32.8pp	-461.5%	60.5%+80.8pp	8.1%+20.1pp	3.1%+14.7pp	0.0%+38.2pp	-20.4%+45.7pp	-12.0%+29.7pp
Return on Assets	14.1%+12.9pp	-155.2%-155.2pp	47.8%+53.3pp	2.9%+5.8pp	1.1%+3.8pp	0.0%+7.6pp	-5.5%+6.5pp	-2.9%+4.0pp
Current Ratio	2.32+0.1x	1.91-1.0x	2.06-0.6x	1.87-0.9x	2.25-0.6x	2.93-0.8x	2.63-0.7x	2.78-2.8x
Asset Turnover	0.390.0x	0.340.0x	0.79+0.5x	0.36+0.1x	0.36+0.1x	0.30+0.1x	0.27+0.1x	0.24+0.1x
FCF Margin	47.7%+22.5pp	-39.8%-20.8pp	71.6%+76.1pp	25.3%+18.3pp	25.2%+26.6pp	-19.0%+39.1pp	-4.5%+5.7pp	7.0%+31.1pp

Not reported in any period shown, so not listed: Return on Equity, Debt-to-Equity.

Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin.

Note: Shareholder equity is negative (-$119.2M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.

Company	Fiscal year	Revenue	Net income	Net margin	Market cap	Health score
BioCryst Pharmaceuticals Inc BCRX	FY2025	$874.8M	$263.9M	30.2%	$2.2B	74/100
Avadel Pharmaceuticals plc AVDL	FY2024	$169.1M	-$48.8M	-28.9%	$2.1B	53/100
Harrow, Inc. HROW	FY2025	$272.3M	-$5.1M	-1.9%	$1.1B	52/100
Phibro Animal Health Corporation PAHC	FY2026	$1.5B	$99.7M	6.6%	$1.5B	60/100
BGM Group Ltd. BGM	FY2025	$37.9M	-$19.9M	-52.6%	$133.0M	28/100
Amphastar Pharmaceuticals, Inc. AMPH	FY2025	$719.9M	$98.1M	13.6%	$1.1B	70/100

Where BioCryst Pharmaceuticals Inc Ranks

Frequently Asked Questions

What is BioCryst Pharmaceuticals Inc's annual revenue?

BioCryst Pharmaceuticals Inc (BCRX) reported $874.8M in total revenue for fiscal year 2025. This represents a 94.1% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is BioCryst Pharmaceuticals Inc's revenue growing?

BioCryst Pharmaceuticals Inc (BCRX) revenue grew by 94.1% year-over-year, from $450.7M to $874.8M in fiscal year 2025.

Is BioCryst Pharmaceuticals Inc profitable?

Yes, BioCryst Pharmaceuticals Inc (BCRX) reported a net income of $263.9M in fiscal year 2025, with a net profit margin of 30.2%.

What is BioCryst Pharmaceuticals Inc's EBITDA?

BioCryst Pharmaceuticals Inc (BCRX) had EBITDA of $342.4M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

How much debt does BioCryst Pharmaceuticals Inc have?

As of fiscal year 2025, BioCryst Pharmaceuticals Inc (BCRX) had $89.7M in cash and equivalents against $0 in long-term debt.

What is BioCryst Pharmaceuticals Inc's gross margin?

BioCryst Pharmaceuticals Inc (BCRX) had a gross margin of 97.8% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is BioCryst Pharmaceuticals Inc's operating margin?

BioCryst Pharmaceuticals Inc (BCRX) had an operating margin of 39.0% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is BioCryst Pharmaceuticals Inc's net profit margin?

BioCryst Pharmaceuticals Inc (BCRX) had a net profit margin of 30.2% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is BioCryst Pharmaceuticals Inc's free cash flow?

BioCryst Pharmaceuticals Inc (BCRX) generated $344.9M in free cash flow during fiscal year 2025. This represents a 749.0% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is BioCryst Pharmaceuticals Inc's operating cash flow?

BioCryst Pharmaceuticals Inc (BCRX) generated $347.4M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are BioCryst Pharmaceuticals Inc's total assets?

BioCryst Pharmaceuticals Inc (BCRX) had $514.2M in total assets as of fiscal year 2025, including both current and long-term assets.

What are BioCryst Pharmaceuticals Inc's capital expenditures?

BioCryst Pharmaceuticals Inc (BCRX) invested $2.5M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does BioCryst Pharmaceuticals Inc spend on research and development?

BioCryst Pharmaceuticals Inc (BCRX) invested $166.1M in research and development during fiscal year 2025.

How many shares does BioCryst Pharmaceuticals Inc have outstanding?

BioCryst Pharmaceuticals Inc (BCRX) had 251M shares outstanding as of fiscal year 2025.

What is BioCryst Pharmaceuticals Inc's current ratio?

BioCryst Pharmaceuticals Inc (BCRX) had a current ratio of 2.06 as of fiscal year 2025, which is generally considered healthy.

What is BioCryst Pharmaceuticals Inc's return on assets (ROA)?

BioCryst Pharmaceuticals Inc (BCRX) had a return on assets of 51.3% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is BioCryst Pharmaceuticals Inc's P/E ratio?

BioCryst Pharmaceuticals Inc (BCRX) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to June 30, 2026). The market capitalization is $2.2B as of Oct 10, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is BioCryst Pharmaceuticals Inc's price-to-sales ratio?

BioCryst Pharmaceuticals Inc (BCRX) trades at 2.3x sales, its market capitalization divided by revenue of $940.6M revenue, trailing 12 months to June 30, 2026. The market capitalization is $2.2B as of Oct 10, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

Why is BioCryst Pharmaceuticals Inc's debt-to-equity ratio negative or not reported?

BioCryst Pharmaceuticals Inc (BCRX) has negative shareholder equity of -$119.2M as of fiscal year 2025, so no debt-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.

What is BioCryst Pharmaceuticals Inc's Altman Z-Score?

BioCryst Pharmaceuticals Inc (BCRX) has an Altman Z-Score of 2.34, placing it in the Grey Zone (moderate risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is BioCryst Pharmaceuticals Inc's Piotroski F-Score?

BioCryst Pharmaceuticals Inc (BCRX) has a Piotroski F-Score of 7 out of 9, indicating strong financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are BioCryst Pharmaceuticals Inc's earnings high quality?

BioCryst Pharmaceuticals Inc (BCRX) has an earnings quality ratio of 1.32x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can BioCryst Pharmaceuticals Inc cover its interest payments?

BioCryst Pharmaceuticals Inc (BCRX) has an interest coverage ratio of 4.32x, meaning it can adequately cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

How financially healthy is BioCryst Pharmaceuticals Inc?

BioCryst Pharmaceuticals Inc (BCRX) scores 74 out of 100 on our Financial Health Score, indicating strong standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.